Clinical Trial Update: Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating anlotinib with radiotherapy for resectable soft tissue sarcoma at high risk of recurrence.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Ruijin Hospital | Conditions: Soft Tissue Sarcoma, High Risk of Recurrence | Phase 2 | Status: UNKNOWN